secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2026-06-29T22:54:48+00:00
Accession:  0001856725-26-000003
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics appoints Nicholas Maestas as CFO, approves 2026 Equity Inducement Plan
--------------------------------------------------------------------------------

- Nicholas Maestas appointed CFO effective June 29, 2026, succeeding Svai Sanford.
- Maestas previously CFO of Tempest Therapeutics; base salary $500,000, target bonus 75%.
- Maestas receives inducement option for 2,000,000 shares vesting over 4 years.
- Board approved 2026 Equity Inducement Plan reserving 5,500,000 shares for new hires.
- Plan allows inducement grants under Nasdaq Rule 5635(c)(4) without stockholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000185672526000003/0001856725-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000185672526000003/rani-20260624.htm
  HTML page:      https://secwatch.observer/filing/0001856725-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer